Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 20 articles:
HTML format



Single Articles


    July 2022
  1. YE B, Sheng Y, Zhang M, Hu Y, et al
    Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
    Cancer Lett. 2022;538:215691.
    PubMed     Abstract available


    May 2022
  2. ZHENG NS, Zhao XY, Wei D, Miao JL, et al
    CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia.
    Cancer Lett. 2022;542:215762.
    PubMed     Abstract available


    April 2022
  3. YOU R, Wang B, Chen P, Zheng X, et al
    Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells.
    Cancer Lett. 2022;532:215582.
    PubMed     Abstract available


    March 2022
  4. GHIRALDELI L, Anderson R, Pladna K, Pardee TS, et al
    Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML).
    Cancer Lett. 2022;535:215659.
    PubMed     Abstract available


    February 2022
  5. ZHOU Y, Guan L, Li W, Jia R, et al
    DT7 peptide-modified lecithin nanoparticles co-loaded with gamma-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.
    Cancer Lett. 2022 Feb 28:215608. doi: 10.1016/j.canlet.2022.215608.
    PubMed     Abstract available


  6. YAO K, Liu H, Yu S, Zhu H, et al
    Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.
    Cancer Lett. 2022;533:215603.
    PubMed     Abstract available


  7. PATEL SA
    Functional genomic approaches in acute myeloid leukemia: Insights into disease models and the therapeutic potential of reprogramming.
    Cancer Lett. 2022 Feb 3:215579. doi: 10.1016/j.canlet.2022.215579.
    PubMed     Abstract available


    January 2022
  8. GHANI LA, Yusenko MV, Frank D, Moorthy R, et al
    A synthetic covalent ligand of the C/EBPbeta transactivation domain inhibits acute myeloid leukemia cells.
    Cancer Lett. 2022 Jan 22. pii: S0304-3835(22)00040.
    PubMed     Abstract available


    December 2021
  9. KAMACHI K, Ureshino H, Watanabe T, Yoshida N, et al
    Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.
    Cancer Lett. 2021 Dec 4. pii: S0304-3835(21)00607.
    PubMed     Abstract available


    November 2021
  10. YUSENKO MV, Biyanee A, Andersson MK, Radetzki S, et al
    Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
    Cancer Lett. 2021;520:132-142.
    PubMed     Abstract available


    July 2021
  11. LIU Q, Hua M, Zhang C, Wang R, et al
    NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1beta/Th1/IFN-gamma in acute myeloid leukemia.
    Cancer Lett. 2021 Jul 5. pii: S0304-3835(21)00299.
    PubMed     Abstract available


    May 2021
  12. TAVAKOLI SHIRAZI P, Eadie LN, Page EC, Heatley SL, et al
    Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Cancer Lett. 2021;512:28-37.
    PubMed     Abstract available


    April 2021
  13. LING Y, Xu N, Zhao K, Han L, et al
    Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia.
    Cancer Lett. 2021;510:59-66.
    PubMed     Abstract available


  14. LEE DH, Kang SH, Choi DS, Ko M, et al
    Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells.
    Cancer Lett. 2021;510:37-47.
    PubMed     Abstract available


  15. LI Y, Li Y, Yin J, Wang C, et al
    A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
    Cancer Lett. 2021 Apr 13. pii: S0304-3835(21)00157.
    PubMed     Abstract available


    March 2021
  16. GLENEADIE HJ, Baker AH, Batis N, Bryant J, et al
    The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.
    Cancer Lett. 2021;501:172-186.
    PubMed     Abstract available


    August 2020
  17. YANG W, Liu S, Li Y, Wang Y, et al
    Pyridoxine induces monocyte-macrophages death as specific treatment of acute myeloid leukemia.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30432.
    PubMed     Abstract available


  18. ZHANG LP, Lu AD, Wu J, Jia YP, et al
    Expanded activated autologous lymphocyte infusions improve outcomes of low- and intermediate-risk childhood acute myeloid leukemia with low level of minimal residual disease.
    Cancer Lett. 2020 Aug 20. pii: S0304-3835(20)30415.
    PubMed     Abstract available


    July 2020
  19. YANG H, Zhou H, Huang Z, Tao K, et al
    Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides.
    Cancer Lett. 2020;482:44-55.
    PubMed     Abstract available


    January 2020
  20. FORGIONE MO, McClure BJ, Eadie LN, Yeung DT, et al
    KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
    Cancer Lett. 2020;469:410-418.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: